Searchable abstracts of presentations at key conferences in endocrinology

ea0022p418 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?

Leboulleux Sophie , Deandreis Desiree , Ghuzlan Abir Al , Auperin Anne , Dromain Clarisse , Young Jacques , Schlumberger Martin , Baudin Eric

Context: Peritoneal carcinomatosis (PC) is a rare site of distant metastasis in patients with adrenocortical cancer (ACC). One preliminary study suggests an increase risk of PC after adrenalectomy through laparoscopic approach of ACC.Objective: The objective of the study was to search for risk factors of PC including surgical approach. This was a retrospective cohort study conducted in an institutional practice.Patients: Sixty-four...

ea0032p544 | Endocrine tumours and neoplasia | ECE2013

Multimodal combination of interferon and loco-regional treatment for disease control in progressive metastatic pheochromocytoma/paraganglioma patients

Hadoux Julien , Deandreis Desiree , Caramella Caroline , Leboulleux Sophie , Al Ghuzlan Abir , Chougnet Cecile , Dumont Frederic , Deschamps Frederic , Schlumberger Martin , Baudin Eric

Interferon-α (IFN-α) has shown some activity in neuroendocrine tumors with disease stabilizations. Malignant pheochromocytoma and paraganglioma (MPPGLs) have a heterogeneous behavior with a slow progression rate, most of the time and a high frequency of bone metastases. Stabilizing disease and preventing skeletal-related events are two goals to achieve in the management of MPPGLs patients.This retrospective study evaluated a multimodal strategy...

ea0029oc9.1 | Endocrine Tumours &amp; Translation | ICEECE2012

The Young Investigator Winner

Hadoux J. , Leboulleux S. , Al Ghuzlan A. , Borget I. , Caramella C. , Chougnet C. , Young J. , Dumont F. , Deschamps F. , Schlumberger M. , Baudin E.

Malignant pheochromocytoma and paraganglioma (PPGLs) are rare diseases with a heterogeneous behaviour. 131I-MIBG therapy and the cyclophosphamide-dacarbazine-vincristine chemotherapy regimen (CVD) constitute the most popular options in the metastatic setting. We have investigated the antitumor effect of temozolomide (TMZ), in patients with metastatic PPGLs. Efficacy was primary endpoint, safety and identification for prognosis factors of response were secondary endpoints.<...

ea0022p29 | Adrenal | ECE2010

Benefit to risk ratio of mitotane high starting dose strategy in 22 patients with adrenocortical carcinoma (ACC): a prospective evaluation

Mauclere-Denost Sophie , Leboulleux Sophie , Borget Isabelle , Al Ghuzlan Abir , Young Jacques , Drouard Laurence , Paci Angelo , Chanson Philippe , Schlumberger Martin , Baudin Eric

Background: The benefit to risk ratio of mitotane high starting dose regimen in ACC remains unknown.Methods: To evaluate a high starting dose strategy, we performed a single-center, prospective study with three main objectives: 1) to assess the time taken to reach a mitotane plasma level above 14 mg/l (benefit); 2) to evaluate mitotane tolerance (risk) in the first 3 months of treatment and 3) to analyse the correlation using a regression analysis test b...

ea0090p651 | Endocrine-related Cancer | ECE2023

Impact of vascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study

Marques Puga Francisca , Al Ghuzlan Abir , Hartl Dana M. , Bani Mohamed-Amine , Moog Sophie , Pani Fabiana , Breuskin Ingrid , Guerlain Joanne , Faron Matthieu , Denadreis Desiree , Baudin Eric , Hadoux Julien , Lamartina Livia

Background: Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown.Objective: To evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs. <p class="abste...

ea0032p11 | Adrenal cortex | ECE2013

Molecular screening for personalized treatment approach in advanced adrenocortical cancer

De Martino Maria Cristina , Al Ghuzlan Abir , Do Cao Christine , Assie Guillaume , Scoazec Jean-Yves , Leboulleux Sophie , Aubert Sebastien , Libe Rossella , Nozieres Cecile , Pattou Francois , Borson-Chazot Francoise , Pivonello Rosario , Mazoyer Clement , Bertherat Jerome , Schlumberger Martin , Lacroix Ludovic , Baudin Eric

Propose: To screen for the presence of putative targets for new treatments in a large cohort of advanced adrenocortical cancer (ACC)Experimental design: In 40 adult stage III-IV ACC primary samples, we used comparative genomic hybridization (CGH) and hotspot gene sequencing (with Ion Torrent) to describe the presence of copy number abnormalities and mutations in more than 40 genes involved in cancer development and putative drug sensitivity (HER2; EGFR; ...

ea0022p416 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma characterized for plasma mitotane level and ERCC1 protein expression analyses

Malandrino Pasqualino , Ghuzlan Abir Al , Castaing Marine , Young Jacques , Caillou Bernard , Travagli Jean-Paul , Elias Dominique , de Baere Thierry , Dromain Clarisse , Chanson Philippe , Schlumberger Martin , Leboulleux Sophie , Baudin Eric

Introduction: Mitotane and platinum-based chemotherapy are the main therapeutic choices for treating inoperable and/or metastatic adrenocortical carcinoma (ACC).Objective: To search for prognostic parameters of survival in patients with metastatic ACC treated with combined mitotane- and platinum-based chemotherapy.Patients: One hundred and thirty one consecutive patients with metastatic ACC treated at the Gustave-Roussy Institute (...

ea0092ps2-17-06 | Thyroid Cancer Diagnosis 2 | ETA2023

Impact of lymphovascular invasion on otherwise low-risk papillary thyroid carcinomas: A retrospective and observational study

Puga Francisca , Al Ghuzlan Abir , Hartl Dana M. , Bani Mohamed-Amine , Moog Sophie , Pani Fabiana , Breuskin Ingrid , Guerlain Joanne , Faron Matthieu , Denadreis Desiree , Baudin Eric , Hadoux Julien , Lamartina Livia

Background: Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown.Objective: To evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs.<p class="abstex...

ea0063p433 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Molecular events in a large series of advanced stage III-IV adrenocortical cancer: looking for new therapeutic options

De Martino Maria Cristina , Lacroix Ludovic , Aubert Sebastien , Libe Rossella , Al Ghuzlan Abir , de la Fouchardiere Christelle , Hescot Segolene , Assie Guillaume , Honore Aurelie , Deschamps Fred , Lombes Marc , Borson-Chazot Francoise , Pattou Francois , Pivonello Rosario , Borget Isabelle , Schlumberger Martin , Leboulleux Sophie , Scoazec Jean-Yves , Bertherat Jerome , Cao Christine Do , Baudin Eric

Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and scant treatment options.Purpose: To look for new therapeutic approaches issued from the screening for common genetic variants in a large series of advanced ACC.Experimental design: Whole exome sequencing have been performed in 10 advanced (stage III and IV) ACC samples to identify the recurrent variants. The presence and the frequency of most interesting variants ...

ea0026p70 | Endocrine tumours and neoplasia | ECE2011

First prognostic analysis of stage III adrenocartical carcinoma patients after complete resection: a retrospective French Multicentric Study from the INCA-COMETE network

Do Cao C , Leboulleux S , Borget I , Bertherat J , De la Fouchardiere C , Hecart A C , Caron P , Tabarin A , Niccoli P , Rohmer V , Drui D , Schillo F , Raingeard I , Young J , Ghuzlan A , Borson-Chazot F , Bertagna X , Pattou F , Wemeau J L , Francis Z , Libe R , Aubert S , Baudin E

Objective: To assess outcome of stage III–ENSAT adrenocortical carcinoma (ACC) patients after complete macroscopic resection and prognostic factors for disease-free survival (DFS) and overall survival (OS).Methods: A retrospective review of 68 stage III ACC patients treated surgically between 1994 and 2009 in the French COMETE network was performed. Characteristics of patients were reviewed by a single investigator as well as the Weiss score by expe...